Accelerating High-Concentration Formulation Development for Antibodies and Novel Biologics with a Strategic, Stepwise Approach

In this white paper, we share how a stepwise formulation development strategy, combining in silico and in vitro assessments, high‑throughput screening, and design‑of‑experiment methodologies, can help overcome these challenges and accelerate timelines. Discover real‑world case studies, practical insights, and proven approaches to de‑risking high‑concentration formulation development for antibodies and next‑generation biologics.